Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: MCsweet who wrote (1169)	11/1/2003 1:58:14 PM
From: Tomato	Read Replies (2) \| Respond to of 1833

I got the idea about a rights offering from Michelle Paige, the CEO, who said she was looking at companies to buy in the $30 mil to $90 mil price range (if I remember that right--I might be a little off, like $30 mil to $100 mil) and that KDUS could use combinations of cash, debt, and/or a SH rights offering to pay for it. Re your other point, I think Carl Icahn has control of any decision notwithstanding what members of this thread own. I'm still optimistic - it's just that up until now I could never come up with a scenario where we could get shafted...but now I can sort of see it. Always have to consider the worst case scenario. Maybe you can tell me what the worst case is...Assume they announce that they're buying XYZ Co. for $90 mil and will pay $20 mil. cash and issue stock in a rights offering for $70 mil. I'm guessing the price of KDUS would move based on the market's perceived value of the company. If it was a great deal the KDUS price might go above KDUS's cash/stock/tax loss/licenses-royalties value? I guess Carl wouldn't OK a deal that wouldn't make him money..but I guess the $64,000 question is could an acquisition occur that caused the KDUS price to go way below the $2+/sh cash and stock and etc. and be something that could screw us and help Carl to pick up more shares at a price under the $2+/sh?